700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Review Article Open Access
Losartan is an orally active, non-peptide Angiotensin II (AT1specific) antagonist. It is a new and promising antihypertesive agent, better than ACE inhibitors in controlling hypertesion. Its antihypertensive effect is enhanced when given in combination with hydrochlorthiazide (HCT) or an ACE inhibitor. Among other angiotensin receptor antagonists are TCV- 116, CV-11974, and CV-11194, all of which seem to be promising antihypertensives of the future. Results of the studies on losartan and other angiotensin receptor antagonists indicate that they would certainly acquire a commanding position in the treatment of hypertension, a disease that makes millions of people suffer.
To read the full article Peer-reviewed Article PDF
Author(s): Zeenat S Hakim Milan C Satia Ramesh K Goyal